Clinical Trials Logo

Marfan Syndrome clinical trials

View clinical trials related to Marfan Syndrome.

Filter by:

NCT ID: NCT00566488 Completed - Hypoparathyroidism Clinical Trials

Parathyroid and Thymus Transplantation in DiGeorge #931

Start date: January 2005
Phase: Phase 1
Study type: Interventional

This study has three primary purposes: to assess parathyroid function after parathyroid transplantation in infants with Complete DiGeorge syndrome; to assess immune function development after transplantation; and, to assess safety and tolerability of the procedures. This is a Phase 1, single site, open, non-randomized clinical protocol. Enrollment is closed and study intervention is complete for all enrolled subjects; but subjects continue for observation and follow-up. Subjects under 2 years old with complete DiGeorge syndrome (atypical or typical) received thymus transplantation. Subjects received pre-transplant immune suppression with rabbit anti-human-thymocyte-globulin. Subjects with hypoparathyroidism and an eligible parental donor received thymus and parental parathyroid transplantation. A primary hypothesis: Thymus/Parathyroid transplant subjects will need less calcium and/or calcitriol supplementation at 1 year post-transplant as compared to historical controls.

NCT ID: NCT00485368 Completed - Marfan Syndrome Clinical Trials

Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

Start date: January 2004
Phase: Phase 3
Study type: Interventional

The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.

NCT ID: NCT00429364 Completed - Marfan Syndrome Clinical Trials

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network

Start date: January 2007
Phase: Phase 3
Study type: Interventional

Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this condition die because of the associated heart and blood vessel abnormalities. This study will compare the effectiveness of two medications, losartan and atenolol, at slowing aortic root enlargement in individuals with Marfan syndrome.

NCT ID: NCT00270686 Completed - Marfan Syndrome Clinical Trials

Studies of Heritable Disorders of Connective Tissue

Start date: January 21, 2003
Phase:
Study type: Observational

Background: - Heritable disorders of connective tissue are genetic conditions that can affect the skin and other parts of the body. They are related to mutations in genes that are responsible for building tissues. The symptoms differ among disorders. Researchers want to study which genes may be responsible for different disorders. They will be performing a long-term (up to 10 years) study and a study that requires a single visit. These studies will look at how these disorders affect the body and what genes may cause these conditions. Objectives: - To perform one-time and long-term studies of people who have heritable disorders of connective tissue. Eligibility: - Individuals at least 2 years of age who have or may have a heritable disorder of connective tissue. Design: - Participants will be screened with a physical exam, medical history, and blood samples. - Participants will be on one of two parts of this study. The longitudinal arm will require long-term study over about 10 years. The mutational analysis arm will involve a single visit. - Longitudinal arm participants must be at least 12 years of age. They will have study visits at regular intervals for up to 10 years. The tests given at these visits may include all or some of the following: - Blood, saliva, urine, and skin samples - Heart and lung function tests - Magnetic resonance imaging scans of the neck, chest, spine, and abdomen - Other imaging studies such as x-rays, bone density scans, and ultrasounds - Questionnaires about sleep, pain, and quality of life - Photographs of affected areas. - Mutational analysis arm participants will have a single study visit. They will provide blood and saliva samples. They will provide tissue from a skin biopsy. They will also let the researchers take photos of any affected body parts. They will complete questionnaires about sleep, pain, and quality of life.

NCT ID: NCT00001641 Completed - Marfan Syndrome Clinical Trials

Study of Heritable Connective Tissue Disorders

Start date: March 1997
Phase: N/A
Study type: Observational

The purposes of this study are to identify the genes responsible for inherited connective tissue disorders and learn about the range of medical problems they cause. It will investigate whether specific gene changes cause specific medical problems and will establish diagnostic criteria (signs and symptoms) for the individual syndromes. Children and adults with a known or suspected inherited connective tissue disorder (Marfan, Ehlers-Danlos or Stickler syndrome, or other closely related disorders) and their family members may be eligible for this study. Patients enrolled in the study will have a medical history, physical examination and blood tests, as well as other procedures that may include: - Echocardiogram (ultrasound of the heart) - X-rays and other imaging studies, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scans - Lung function studies - Urine tests - Skin biopsy (removal of a small piece of tissue, under local anesthetic, for microscopic examination) - Examination by various specialists (e.g., in ophthalmology, gastroenterology, rehabilitation medicine) as needed - Questionnaires regarding chronic pain and fatigue, quality of life, and the impact of the connective tissue disorder on the patient and family. (Patients who wish to enroll but cannot travel to NIH may have a more limited participation, including review of medical records, telephone interview regarding personal and family history, and collection of a specimen (blood, skin biopsy, or other) for genetic testing. Patients will be notified of genetic testing results that show a change responsible for their connective tissue disorder. If they wish, the information will also be sent to their local health care provider, along with recommendations for additional tests or treatment options. No treatment is offered as part of this study. Participating family members who do not themselves have a connective tissue disorder will provide a small blood sample for gene testing and be interviewed by telephone about their personal and family health history. Those whose blood test results show a gene change associated with a connective tissue disorder will be invited to NIH for a discussion of the findings or referred to a genetic center in their area.